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1. Introduction 
Some glycoproteins, uch as fetuin and orosomu- 
coid, after sialic acid removal and consequent expo- 
sure of galactose residues are selectively taken up by 
hepatocytes where they are hydrolyzed in lysosomes 
[l-3]. These desialylated glycoproteins have been 
used as carriers for introducing proteins [4] and lipo- 
somes [S] in parenchymal liver cells. We have coupled 
trifluorothymidine (FsT) to asialofetuin (AF) [6] 
in order to selectively concentrate an inhibitor of 
DNA synthesis into hepatocytes. The resulting conju- 
gate (FsT-AF) was employed as an approach to the 
lysosomotropic [7,8] treatment of hepatitis caused 
by deoxyriboviruses [6,9,10]. FsT coupled to AF 
caused an inhibition of viral DNA synthesis in liver of 
Ectromella virus-infected mice which was >3-times 
greater than that produced by the free drug. On the 
contrary inhibition of DNA synthesis in bone marrow 
was the same when FsT was administered either cou- 
pled to AF or as a free drug [6]. The inhibition of 
DNA synthesis caused by FsT-AF in bone marrow 
appears to be due to FsT released from the conjugate 
inside the hepatocytes and escaped from these cells 
into the blood [6]. 
Contrary to other inhibitors of DNA synthesis, 
such as cytosine-I +-D-arabinofuranoside and adenine- 
9P-D-arabinofuranoside (ara-A), FsT is not used as a 
systemic antiviral drug in man because of its toxicity. 
ara-A has been employed in the treatment of human 
chronic hepatitis B (HB) infection [ 11-l 3 1. It inhibits 
HB virus replication [1 1 - 131 but produces ide 
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effects, mainly gastrointestinal symptoms [11 ,I 41 
which are most likely due to its inhibitory effect 
on the dividing cells of gastric and intestinal mucosa. 
These side effects could be avoided or reduced by 
concentrating ara-A into hepatocytes. We report here 
the conjugation of ara-A and ara-A 5’-monophosphate 
ara-A and ara-AMP were administered to Ectromelia 
activity as ara-A [ 151. The conjugates as well as free 
ara-A and ara-AMP were administered to Extromelia 
virus-infected mice, during the phase of virus replica- 
tion in hepatocytes [6], and their effect on virus 
DNA synthesis in liver and on cell DNA synthesis in 
the intestine was determined. 
2. Materials and methods 
2.1. ara-A and ara-AMP conjugates 
Fetuin (Sigma type III) was desialylated by 
neuraminidase according to [ 161. 
The conjugate of ara-A (ara-A-glut-AF) was 
obtained by coupling ara-A-glutarate to AF via its 
hydroxysuccinimide ester. 500 mg ara-A (1.87 mmol) 
(Serva, D-69 Heidelberg: dried at 80°C overnight 
over P401,-, in vacua) was dissolved in 10 ml pyridine, 
and glutaric anhydride (259 mg, 2.27 mmol) was 
added over 2 h with stirring, at 80°C and left over- 
night at the same temperature. The solvent was eva- 
porated, the residue was dissolved in 1.5% aqueous 
acetic acid and chromatographed on a Sephadex 
LH-20 column (200 X 3 cm). Fractions 15-28 (each 
fraction 20 ml) were evaporated and rechromato- 
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graphed on the same column; fractions 47-5 6 (10 
ml each) contained ara-A glutarate and were lyo- 
philized (120 mg) (high-voltage paper electrophoresis 
at pH 6.5 showed the presence of a main band which 
migrated to the anode). The product (120 mg, 0.3 15 
mmol) was dissolved in 5 ml dimethylformamide and 
N-hydroxysuccinimide (43 mg, 0.37 mmol) and 
dicyclohexylcarbodimide (77 mg, 0.37 mmol) were 
added gradually at 4°C. After 72 h at the same 
temperature the precipitate was filtered off and the 
solution added to 200 mg AF dissolved in 20 ml 
water, maintaining 4°C and pH 6-7; after the addi- 
tion (4 h), the solution was left overnight at the same 
temperature, then dialyzed and lyophilized. The 
product was dissolved in 10 ml 0.05% ammonium 
bicarbonate solution, and chromatographed through 
a Sephadex G-75 column (100 X 2 cm) and eluted 
with the same solvent, and lyophilized. Two fractions 
(AB) were collected (150 and 21 mg), with a 80% 
protein content as determined by the method in [ 171 
and 8 mol ara-A/mol AF (UV spectrophotometry). 
Sodium dodecyl sulphate (SDS)-polyacrylamide 
gel electrophoresis showed that fraction A contained 
polymers of AF whereas fraction B contained the 
monomeric form of AF. ara-AMP was coupled to 
AF (ara-AMP-AF) by a water-soluble carbodiimide 
as in [ 181.60 mg 1 -ethyl-3-(dimethyl_aminopropyl)- 
carbodiimide (ECDI) (Fluka) dissolved in 200 ~1 
Hz0 was added to 60 mg ara-AMP dissolved in 1 ml 
Hz0 by addition of NaHCOs (pH 5). After 10 min at 
25’C, 30 mg AF dissolved in 300 ~1 Hz0 (adjusted to 
pH 7 with NaOH), was added with shaking. The 
mixture was incubated at 25°C for 24 h, then 
chromatographed on a Sephadex G-100 column 
(1.6 X 90 cm) equilibrated and eluted with 0.15 
M NaCl. The conjugated material emerged in two 
peaks. SDS-polyacrylamide gel electrophoresis 
showed that the first peak contained polymers of AF, 
whereas the second peak contained the monomeric 
form of AF. Fractions corresponding to the second 
peak were pooled, dialyzed against water and lyo- 
philized. The yield in monomeric form of the conju- 
gate (ara-AMP-AF) was 10 mg. Three different 
preparations were made by this procedure (IJI,III). 
The molar ratio of ara-AMP:AF in the conjugates 
ranged from 3.5-4 as determined spectrophoto- 
metrically. In a separate xperiment AF was main- 
tamed in the presence of ara-AMP with the same 
procedure used for the preparation of ara-AMP-AF, 
except hat ECDI was omitted. After incubation at 
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25°C for 24 h ara-AMP was removed by gel filtration. 
No ara-AMP was found adsorbed onto AF as assessed 
by spectrophotometric measurement, indicating that 
in the conjugates ara-AMP is linked to AF by a 
covalent bond. Probably conjugation takes place 
mostly by formation of an amide bond between the 
e-NH2 group of lysine in AF and the phosphate 
group of ara-AMP, as shown in an analogous reac- 
tion using carbodiimides for coupling thymidilic 
acid to albumin [18]. 
2.2. Blood clearance of labeled AF 
The blood clearance of “C-labelled AF in mice in 
the presence of cold non-conjugated AF, ara-A-glut- 
AF and ara-AMP-AF was determined as in [6]. 
2.3. DNA synthesis in liver and intestine of 
Ectromelia virus-infected mice 
Ectromelia virus (Hampstead mouse strain) was 
grown in L-929 cells and purified according to 
[ 19,201. In each experiment 14 Swiss male mice 
(28-31 g) were injected intravenously (i.v.) with 
Ectromelia virus at the multiplicity of 2 X lo5 
p.f.u./g body wt, corresponding to 300-times the 
LDsc. 44 h after infection, i.e., during the phase of 
virus replication in hepatocytes [6], mice were 
divided in 2 groups of 7 animals each. Animals of 
one group were used as controls. Animals of the other 
group were inoculated intraperitoneally (i.p.) with 2’- 
deoxycoformycin (an inhibitor of ara-A deamination 
[21,22]) (2 lg/g body wt) and 45 min later received 
an i.v. injection of the antiviral compound to be 
tested. After 45 min animals of treated and control 
groups were injected i.p. with [methyl-3H] thymidine 
(spec. act. 24 Ci/mmol) at 30 &i/animal. Thirty min 
after [methyli3H] thymidine administration mice 
were killed and liver as well as a tract of intestine 
(4 cm long starting from pylorus) were rapidly 
removed. DNA was extracted from these tissues 
according to [23] its radioactivity was counted and 
concentration was measured according to [24]. 
Administration of 2’-deoxycoformycin was 
necessary because ara-A is >lOO-times less active in 
rodents than in primates, due to its rapid inactivation 
mostly by oxidation at C-2 position and in part by 
deamination [25]. In fact, doses of ara-A and ara- 
AMP alone up to 5 pg (19 nmol) and 10 pg (29 nmol)/g 
body wt , respectively, did not produce any significant 
inhibition of DNA synthesis in liver and intestine of 
Ectromelia virus-infected mice. 2’Deoxycoformicin 
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administered alone to Ectromelia virus-infected mice, 
was found to be ineffective on DNA synthesis in 
liver and intestine. 
3. Results and discussion 
Conjugation did not change the capacity of Al? 
to interact with the specific receptors on the surface 
of hepatocytes. Indeed, the clearance of “C-labelled 
AF from the blood of mice was competitively inhib- 
ited to the same extent by the conjugates and by 
an equal amount of non conjugated AF (table 1). 
Table 2 shows that free ara-A and ara-AMP 
produced a greater inhibition of DNA synthesis in 
intestine than in liver. On the contrary ara-A-glut-AF 
and ara-AMP-AF inhibited DNA synthesis in liver 
without producing any significant inhibition in the 
intestine. Doses of conjugated ara-A and ara-AMP 
2-4-times lower than those of the free drugs were 
required to produce a comparable inhibition of DNA 
synthesis in liver. These results indicate that, after 
injection of the conjugates, ara-A and ara-AMP were 
concentrated in the active form into hepatocytes. In 
the case of ara-AMP-AF it cannot be excluded that 
the ester bond linking phosphate to ara-A was not 
broken down in hepatocyte lysosomes so that the 
Table 1 
Effect of cold non-conjugated AF and conjugates on plasma 
clearance of W&belled AF 
Compounds injected 
with W&belled AF 
dpm/ml plasma 
None 54 900 
AF 112 000 
ara-A-glut-AF(A) 98 950 
ara-A-glut-AF(B) 120 260 
ara-AMP-AF(1) 123 0.50 
Mice were injected i.v. with 2 pg/g body wt of 14C-labelled 
AF (5 X 1 O6 dpm/mg). Cold AF or conjugates were admin- 
istered i.v. simultaneously with [ W] AF at 20 pg/g body 
wt. After 5 min animals were killed and the radioactivity of 
plasma was measured. Each entry represents he mean 
value of results from 2 animals 
drug released free from the conjugate was ara-A and 
not ara-AMP. 
The rate of uptake of AF by hepatocytes is limited 
(0.2 pg . g body wt-’ . min-’ in the rat [26]). This 
may be the reason why the conjugates did not 
produce an inhibition of DNA synthesis in liver 
>50--59%. A greater inhibition might be obtained in 
animals, such as man, where ara-A is more effective 
than in rodents, even in the absence of 2’deoxy- 
coformicin [25 1. 
Table 2 
Inhibition of DNA synthesis n liver and intestine of Ectromelia virus-infected mice after injection 






(mW8 body W 
Inhibition of DNA synthesis (%) 
Liver Intestine 
1 ara-A 13.1 42 P < O.OOlb 60 P < 0.001 
2 ara-A 18.7 58 P < 0.005 68 P-cO.001 
3 ara-AMP 8.6 57 P < 0.005 60 P-co.001 
4 ara-AMP 17.2 66 P<O.OOl 77 P < 0.001 
5 ara-AMP 34.5 77 P < 0.001 89 P < 0.001 
6 ara-A-glut-AF (A) 5.6 (33)a 38 P < 0.02 15 n.s. 
7 ara-A-glut-AF (B) 1.9 (11) 26 P < 0.05 8 n.s. 
8 ara-A-glut-AF (B) 5.6 (33) 43 P < 0.01 16 n.s. 
9 ara-AMP-AF (I) 1.8 (22) 38 P < 0.005 0 
10 ara-AMP-AF (II) 1.1 (15) 44 P < 0.001 0 
11 ara-AMP-AF (II) 2.2 (30) 59 P < 0.001 19 n.s. 
12 ara-AMP-AF (III) 2.8 (42) 53 P < 0.005 13 n.s. 
a In parentheses the amount of conjugate injected (in pg/g body wt) 
b Results were statistically evaluated by means of Student’s t-test. The difference was considered not 
statistically significant (n.s.) for P < 0.05 
Experimental details are given in section 2.3 
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For the same amount of bound ara-A, ara-AMP-AF 
seemed more effective than ara-A-glut-AF. This 
could depend on the different bonds between the 
drugs and the carrier affecting drug release in lyso- 
somes. 
[6] Fiume, L., Mattioli, A., Balboni, P. G., Tognon, M., 
The use of AF conjugates of ara-A or ara-AMP in 
human chronic hepatitis B should reduce the side 
effects occuring after the use of free ara-A [ 11,141. 
These and similar conjugates could also be useful in 
the treatment of hepatomas, provided that neoplastic 
hepatocytes maintain the receptors for AF. Concen- 
tration of the inhibitor of DNA synthesis in liver cells 
should kill neoplastic proliferating hepatocytes 
without damaging non-dividing normal hepatocytes. 
A drawback in the clinical use of these conjugates 
is the possibility that antibodies could be produced 
against them. This risk might be reduced by admin- 
istering conjugates prepared with galactosylated 
homologous erum albumin. Indeed homologous 
albumin is not immunogenic. In addition, it has been 
found that albumin after galactosylation is selectively 
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